ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition
Item 2.02 of the Current Report on Form8-K filed on February27, 2019 (the “Original Form8-K”) solely to correct certain errors in the press release furnished as Exhibit99.1 thereto (the “Exhibit”). The corrected press release is furnished as Exhibit99.1 hereto. No other changes have been made to the Original Form8-K.

Story continues below

Item 2.02Results of Operations and Financial Condition.

The Exhibit99.1 attached hereto is a replacement of the Exhibitfurnished on the Original Form8-K.

The information in Item 2.02 of this Form8-K/A (including the attached Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Adaptimmune Therapeutics PLC Exhibit
EX-99.1 2 a19-5477_2ex99d1.htm EX-99.1 Exhibit 99.1     Source: Adaptimmune Therapeutics plc February 27,…
To view the full exhibit click here

About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

An ad to help with our costs